Difference between revisions of "DMR Ovariectomy and Butyrate-Enhanced CTA 2"
(added info box) |
(added note) |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
Test of role of ovarian hormones in butyrate-enhanced CTA. Continuation of [[DMP Ovariectomy and Butyrate-Enhanced CTA]]. | Test of role of ovarian hormones in butyrate-enhanced CTA. Continuation of [[DMP Ovariectomy and Butyrate-Enhanced CTA]]. | ||
| + | |||
| + | NOTE: concerned about low bodyweight of rats, amd that butyrate was not freshly made. | ||
{{Infobox experiment|align=right | {{Infobox experiment|align=right | ||
| Line 36: | Line 38: | ||
===Agenda=== | ===Agenda=== | ||
| − | '''Rats arrive''' ( | + | '''Rats arrive''' (Charles River 2021-12-7) |
| − | Female Sprague Dawley rats n=13 (dob | + | Female Sprague Dawley rats n=13 (dob 2021-9-20 |
| Line 45: | Line 47: | ||
3 groups: sham surgery, ovariectomized (ovx), ovariectomized + 3mg pellet of 17-beta-estradiol (Innovative Research, Sarasota, FL) | 3 groups: sham surgery, ovariectomized (ovx), ovariectomized + 3mg pellet of 17-beta-estradiol (Innovative Research, Sarasota, FL) | ||
| − | * DMR | + | * DMR 01-06: Surgery on 2021-12-30 |
| − | * DMR | + | * DMR 07-12: Surgery on 2021-12-31 |
| − | * DMR | + | * DMR 13: Surgery on 2022-1-2 |
Carpofen 0.5 mg/kg pre-op, isoflurane and bupivicaine intra-op, carpofen 0.5 mg/kg post-op (next day). Staples removed 7 days post-op. | Carpofen 0.5 mg/kg pre-op, isoflurane and bupivicaine intra-op, carpofen 0.5 mg/kg post-op (next day). Staples removed 7 days post-op. | ||
| Line 90: | Line 92: | ||
[[Category:Taste Aversion]] | [[Category:Taste Aversion]] | ||
[[Category: CTA Experiments]] | [[Category: CTA Experiments]] | ||
| + | [[Category: Epigenetics]] | ||
Latest revision as of 10:54, 5 July 2022
Test of role of ovarian hormones in butyrate-enhanced CTA. Continuation of DMP Ovariectomy and Butyrate-Enhanced CTA.
NOTE: concerned about low bodyweight of rats, amd that butyrate was not freshly made.
| Ovariectomy and Butyrate-Enhanced CTA 2 | |
|---|---|
| HDAC Sex Difference | |
| Expt Code | DMR |
| Start Date | 2022-1-9 |
| Investigators | Mukherjee, Houpt |
| Funding | Chair's Fund |
| Protocol | 1917 |
| Expt Type | CTA |
| Species | rat |
| Drugs | butyrate, lithium, estradiol |
| Data Link | https://houptlab.org/bartab/expt/?id=DMR |
Dose of NaB based on Kwon and Houpt, Brain Research, 1333 (2010) 36–47, PMID: 20346924 PMCID: PMC2871962
- 0.3 M Na Butyrate = 3.3g/100ml water
- 0.3 M NaCl = 18g/liter water (osmotic control)
Data
People
Durba Mukherjee
Agenda
Rats arrive (Charles River 2021-12-7) Female Sprague Dawley rats n=13 (dob 2021-9-20
Surgery
3 groups: sham surgery, ovariectomized (ovx), ovariectomized + 3mg pellet of 17-beta-estradiol (Innovative Research, Sarasota, FL)
- DMR 01-06: Surgery on 2021-12-30
- DMR 07-12: Surgery on 2021-12-31
- DMR 13: Surgery on 2022-1-2
Carpofen 0.5 mg/kg pre-op, isoflurane and bupivicaine intra-op, carpofen 0.5 mg/kg post-op (next day). Staples removed 7 days post-op.
Day 0: Water removed 2022-1-09
Days 1-7: Water Restriction 2022-1-9 thru 2022-1-17
Weigh rats daily. Water for 10 min, ad lib food.
10 min water at 1400 daily.
Day 8: Conditioning Day 2022-1-18
- 0-30 min: saccharin 0.125%
- at 30 min: 3 ml/kg of 0.15M LiCl ip (all rats)
- at 40 min: 12 ml/kg of 0.3M NaButyrate or NaCl
ad lib water returned after final injection overnight.
Groups:
- Sham + NaCl: DMR04,DMR06,DMR10,DMR12
- Sham + Butyrate: DMR05,DMR11,DMR13
- OVX + NaCl: DMR01, DMR03,DMR08
- OVX + Butyrate: DMR02,FMR07,DMR09
Days 9 - 23: Preference Tests: 2022-1-19 to ????
Rats CTA acquisition and extinction was measured with 24-h, 2-bottle preference tests (for ???? days). Rats were given 24-h free access to both 0.125% saccharin and water bottles, alternating position for 10 days.